Why Is Vir Biotechnology Stock Falling Friday?

Vir Biotechnology's shares tumbled in premarket trading on Friday following the company's announcement of a $150 million equity offering at $10 per share, sparking concerns over potential shareholder dilution. The biopharmaceutical firm priced 15 million common shares, projecting gross proceeds of $150 million before accounting for underwriting fees and expenses.

Underwriters were granted a 30-day option to purchase up to 2.25 million extra shares at the offering price, less any discounts or commissions. The offering is expected to finalize on November 16, pending customary conditions. Lead underwriters include Leerink Partners, Morgan Stanley, and Evercore ISI, with Raymond James serving as co-manager.

Vir Biotechnology is focused on developing therapies for infectious diseases and cancer, with recent advancements in its hepatitis delta and oncology programs. The company recently disclosed positive Phase 3 ECLIPSE 1 results for its investigational hepatitis delta combination, elebsiran and tobevibart, with 79% of treated patients attaining undetectable virus levels at Week 48.

Additionally, Vir's prostate cancer candidate VIR-5500 obtained FDA Fast Track designation, with pivotal trials anticipated to commence in 2027. The company is also progressing oncology candidates VIR-5818 and VIR-5525, alongside other programs utilizing its PRO-XTEN technology.

Despite the recent stock decline, Wall Street maintains a consensus Buy rating for Vir Biotechnology, with an average price target of $24. Morgan Stanley recently upgraded its forecast to $28 on November 10, while Evercore ISI and Needham both increased their price targets to $25 and $24, respectively, on the same day. Technical analysis indicates that Vir Biotechnology is currently trading 11.8% below its 20-day Simple Moving Average (SMA) and 9.5% below its 50-day SMA.

The Relative Strength Index (RSI) stands at 53.54, signaling neutral momentum, while the Moving Average Convergence Divergence (MACD) remains above its signal line, suggesting underlying bullish momentum. Key support is observed at $8.50, while resistance is located at $12, a breakout of which could potentially trigger renewed upward price movement.

Despite recent weakness, the stock remains in a longer-term uptrend, as indicated by a golden cross in December when its 50-day SMA surpassed its 200-day SMA. Vir Biotechnology has experienced a 121.57% increase over the past 12 months and currently trades at 52.9% of its 52-week range, presenting a mixed technical outlook as traders monitor key price levels.

Vir Biotechnology shares closed at $10.11 during premarket trading on Friday, according to Benzinga Pro data.